The first patient has been dosed in a Phase 1 trial testing ACU193, an antibody designed by Acumen Pharmaceuticals…
Articles by Patricia Inacio, PhD
Note: This story was updated Oct. 19, 2021, to better reflect the amount by which Nuravax’s vaccines can raise…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to gantenerumab, a human antibody that’s expected…
Cassava Sciences has launched the first of two Phase 3 clinical trials evaluating the safety and efficacy of simufilam,…
The first patient has been dosed in a Phase 1 study that will test multiple ascending doses of ACD856,…
A partnership agreement will allow INmune Bio to continue using biomarker imaging technology by Imeka in future clinical trials evaluating…
I-Mab will launch a Phase 1 clinical trial evaluating Protollin, its nasal spray immunotherapy candidate for Alzheimer’s disease.
Altoida’s artificial intelligence (AI)-powered device, intended to indicate the start of Alzheimer’s disease in adults with mild dementia but no…
A new Phase 3 trial, a collaboration between Eli Lilly and the Banner Alzheimer’s Institute, is planned to evaluate…
Gosuranemab, an investigational antibody against the tau protein, failed to meet its primary and exploratory efficacy goals in the TANGO…